Skip to main content

Month: June 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

–FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results– SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA) on next steps for the Biologics License Application (BLA) submission with its lead asset, CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). Additionally, Deramiocel has been selected as the proposed International Nonproprietary Name (INN) for CAP-1002 by the World Health Organization. “The last year has been transformative for Capricor as we have moved rapidly towards potential...

Continue reading

The State of Massachusetts Issues MOR-EV Approval, Granting Mullen’s Class 3 EV Truck a $15,000 Cash Voucher per Vehicle Sold

Massachusetts Approves $15,000 Cash Voucher Incentive for Mullen THREE EV TruckMOR-EV program is funded by the MA Executive Office of Energy and Environmental Affairs’ Department of Energy Resources (DOER) and administered statewide by the Center for Sustainable Energy (CSE).Under the MOR-EV program, the Mullen THREE EV truck, with a suggested MSRP of $68,500, now qualifies for a Massachusetts state cash rebate of up to $15,000 When combined with the available $7,500 federal tax credit, the net effective price of the Mullen THREE would be approximately $46,000 BREA, Calif., June 11, 2024 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an electric vehicle (“EV”) manufacturer, announces today the Massachusetts Executive Office of Energy and Environmental Affairs’ Department...

Continue reading

Orocidin – New Insights Into The Treatment Of Periodontitis

Beverly Hills, California., June 11, 2024 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, and its 95% owned subsidiary, Orocidin A/S (“Orocidin”), announced today new insights into the treatment of periodontitis. Orocidin’s preclinical product is called QR-01 and has a novel mode of action. It will be the first ever medical treatment of periodontitis reaching the dental market. The main problem with periodontitis is to treat bacterial infection as well as normalize the immunological function. This concern has highlighted the pressing need for the development of new treatment modalities. OR-01 is specifically designed to...

Continue reading

Definitive Healthcare Wins 2024 Databricks Healthcare and Life Sciences Partner of the Year Award

Empowering healthcare and life science organizations with faster insights through seamless data sharing FRAMINGHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced it has been named the 2024 Databricks Healthcare and Life Sciences Partner of the Year. This prestigious award recognizes Definitive Healthcare’s exceptional collaboration with Databricks in delivering innovative data and AI solutions to the healthcare and life sciences industry. “We are incredibly honored to be recognized by Databricks as their Healthcare and Life Sciences Partner of the Year,” said Casey Eastlack, AVP, Professional Services at Definitive Healthcare. “Our partnership with Databricks enables our shared customers to gain deeper and faster healthcare...

Continue reading

Roaring Onto Kansas Roads: ECD Auto Design Unleashes the Shawnee Commission Jaguar E-Type Coupe

KISSIMMEE, Fla., June 11, 2024 (GLOBE NEWSWIRE) — ECD Auto Design, is thrilled to announce the launch of the Shawnee Commission, a stunning ECD bespoke classic Jaguar E-Type. This one-of-a-kind creation is a meticulously restored and customized Jaguar E-Type Series III Coupe, combining timeless elegance with modern performance, luxury, and unique features. Please find high-resolution images and video HERE. Project Shawnee Commission showcases ECD Auto Design’s commitment to craftsmanship, innovation, and attention to detail. Every aspect of this classic Jaguar E-Type has been thoughtfully reimagined to provide an unparalleled driving experience while honoring the iconic design of the original vehicle. Project Shawnee Commission is a perfect example of ECD Auto Design expertly weaving classic styling with state-of-the-art innovation....

Continue reading

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) — IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time to time, the “Initial Order”) under the Companies’ Creditors Arrangement Act (the “CCAA” and the “CCAA Proceedings”) by the Superior Court of Québec (the “Court”). EY was appointed as monitor (in such capacity, the “Monitor”). On May 27, 2024, the Court granted an order (the “SISP Order”) which i) approved a sale and investment solicitation process to be conducted in respect of the business and/or assets of the Company (the “SISP”), and ii) approved the agreement of purchase and sale between IntelGenx, as vendor, and atai Life Sciences AG, as purchaser, solely for the purpose of constituting...

Continue reading

Arteris Selected by Esperanto Technologies to Integrate RISC-V Processors for High-Performance AI and Machine Learning Solutions

CSRCompiler, an SoC integration automation software solution, enables faster time-to-market and energy-efficient designs for AI inference and HPC applications at a fraction of the cost CAMPBELL, Calif., June 11, 2024 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, today announced that Esperanto Technologies™, a leading developer of high-performance, energy-efficient artificial intelligence (AI) and high-performance computing (HPC) solutions based on the RISC-V instruction set, has chosen Arteris because of design familiarity with CSRCompiler for automation efficiency, error reduction and its integration capabilities. Esperanto will continue to utilize the SoC software to develop its next generation of energy-efficient solutions for AI inference...

Continue reading

SecureTech Announces Removal of OTC Caveat Emptor Designation

ROSEVILLE, Minn., June 11, 2024 (GLOBE NEWSWIRE) — SecureTech Innovations, Inc. (OTC: SCTH), an emerging growth company that develops and markets cutting-edge security and safety devices, products, and technologies such as Top Kontrol and its early-stage cybersecurity and cryptocurrency technology incubator Piranha Blockchain, is pleased to announce that the Caveat Emptor designation has been removed by OTC Markets and SecureTech’s stock is now tradable on the OTC Pink Exchange. SecureTech’s President and CEO Kao Lee commented, “This is a monumental milestone for SecureTech. The Caveat Emptor removal is a direct result of our perseverance and commitment to our shareholders. SecureTech will continue diligently working to maintain the highest level of compliance and transparency with OTC Markets and the Securities and Exchange Commission.” “With...

Continue reading

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries...

Continue reading

NEO Battery Materials Forges Collaboration Agreement with Major South Korean Chemical Material Company, INNOX eco-M

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) — (TSXV: NBM) (OTC: NBMFF)Collaboration Agreement with INNOX eco-M – Leading South Korean Chemical Material Company of Recycled Silicon PowdersSubsidiary of INNOX Holding Corp. – A Producer of Secondary Battery Materials and IT High-Tech Materials with Investment Business OperationsJointly Developing Silicon Anode Products with INNOX eco-M’s High-Purity Recycled SiliconDevelopment Priorities: Enhance Electrochemical Performance, Lower Anode Manufacturing Costs & Environmental Footprint, and Promote Supply Chain ResiliencyNEO Battery Materials Ltd. (“NEO” or the “Company”), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce a collaboration agreement with INNOX eco-M, a company renowned for...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.